Victoza Effective in Youth With Type 2 Diabetes: Study


The injectable diabetes medicine Victoza (liraglutide), a member of the class of medicines known as GLP-1 agonists[1], is effective in children and adolescents ages 10–17 with type 2 diabetes[2], according to a new study in The New England Journal of Medicine[3].

In the phase ELLIPSE study, Victoza combined with metformin[4] significantly reduced A1C[5] levels (a measure of glucose control over the previous 2–3 months) compared to placebo (inactive treatment) with metformin: Victoza reduced A1C by 0.64% and 0.5%, respectively, at 26 and 52 weeks, compared to placebo, which caused a rise of 0.42% and 0.8%.

According to lead researcher William Tamborlane, MD, “These data represent a potential new treatment option for lowering blood sugar in children and adolescents with type 2 diabetes.”

Victoza is currently approved for use along with diet[6] and exercise[7] in adults with type 2 diabetes. Manufacturer Novo Nordisk has submitted the results of the trial to the U.S. Food and Drug Administration (FDA) to support a labeling extension.

Want to learn more about type 2 diabetes in children? Read “Children and Type 2 Diabetes: What’s New?”[8] and “Recognizing Type 2 Diabetes in Children and Adolescents.”[9]

  1. GLP-1 agonists:
  2. type 2 diabetes:
  3. The New England Journal of Medicine:
  4. metformin:
  5. A1C:
  6. diet:
  7. exercise:
  8. “Children and Type 2 Diabetes: What’s New?”:
  9. “Recognizing Type 2 Diabetes in Children and Adolescents.”:

Source URL: